372
W. SHEN, J.-S. KIM, AND J. HILFINGER
2. Yang, L.; Dan, H. C.; Sun, M.; Liu, Q.; Sun, X.-M.; Feldman, R. I.; Hamilton, A. D.;
Polokoff, M.; Nicosia, S. V.; Herlyn, M.; Sebti, S. M.; Cheng, J. Q. AKT=protein kinase
B signaling inhibitor-2, a selective small molecule inhibitor of AKT signaling with
antitumor activity in cancer cells overexpressing AKT. Cancer Res. 2004, 64, 4394–4399.
3. Datta, S. R.; Brunet, A.; Greenberg, M. E. Cellular survival: A play in three AKTS. Genes
Devel. 1999, 13, 2905–2927.
4. Cheng, J. Q.; Nicosia, S. V. AKT signal transduction pathway in oncogenesis. In Encyc-
lopedic Reference of Cancer; D. Schwab (Ed.); Springer: Berlin, Germany, 2001; pp. 35–37.
5. Sun, M.; Wang, G.; Paciga, J. E.; Feldman, R. I.; Yuan, Z. Q.; Ma, X. L.; Shelley, S. A.;
Jove, R.; Tsichlis, P. N.; Nicosia, S. V.; Cheng, J. Q. AKT1=PKBa kinase is frequently
elevated in human cancers and its constitutive activation is required for oncogenic trans-
formation in NIH3T3 cells. Am. J. Pathol. 2001, 159, 431–437.
6. Cheng, J. Q.; Altomare, D. A.; Klein, M. A.; Lee, W.-C.; Kruh, G. D.; Lissy, N. A.; Testa,
J. R. Transforming activity and cell cycledependent expression of the AKT2 oncogene:
Evidence for a link between cell cycle regulation and oncogenesis. Oncogene 1997, 14,
2793–2801.
7. West, K. A.; Castillo, S. S.; Dennis, P. A. Activation of the PI3K=AKT pathway and
chemotherapeutic resistance. Drug Resist. Update 2002, 5, 234–248.
8. O’Connell, M. J.; Rubin, J.; Hahn, R. G.; Kvols, L. K.; Moertel, C. G. Phase II clinical
trial of tricyclic nucleoside phosphate for advanced colorectal cancer. Cancer Treat.
Report 1987, 71 (3), 333–334.
9. Mittelman, A.; Casper, E. S.; Godwin, T. A.; Cassidy, C.; Young, C. W. Phase I study of
tricyclic nucleoside phosphate. Cancer Treat. Report 1983, 67 (2), 159–162.
10. Feun, L. G.; Savaraj, N.; Bodey, G. P.; Lu, K.; Yap, B. S.; Ajani, J.; Burgess, M. A.;
Benjamin, R. S.; McKelvey, E.; Krakoff, I. Phase I study of tricyclic nucleoside phosphate
using a five-day continuous infusion schedule. Cancer Res. 1984, 44 (8), 3608–3612.
11. Schilcher, R. B.; Haas, C. D.; Samson, M. K.; Young, J. D.; Baker, L. H. Phase I
evaluation and clinical pharmacology of tricyclic nucleoside 50-phosphate using a weekly
intravenous regimen. Cancer Res. 1986, 46 (6), 3147–3151.
12. Feun, L. G.; Blessing, J. A.; Barrett, R. J.; Hanjani, P. A phase II trial of tricyclic
nucleoside phosphate in patients with advanced squamous cell carcinoma of the cervix:
a gynecologic oncology group study. Am. J. Clin. Oncol. 1993, 16 (6), 506–508.
13. Hoffman, K.; Holmes, F. A.; Fraschini, G.; Esparza, L.; Frye, D.; Raber, M. N.; Newman,
R. A.; Hortobagyi, G. N. Phase I–II study: Triciribine (tricyclic nucleoside phosphate) for
metastatic breast cancer. Cancer Chemother. Pharmacol. 1996, 37 (3), 254–258.
14. Pu, P.; Kang, C.; Li, J.; Jiang, H.; Cheng, J. The effects of antisense AKT2 RNA on
the inhibition of malignant glioma cell growth in vitro and in vivo. J. Neuro-Oncol.
2006, 76 (1), 1–11.
15. Jiang, J. G.; Chen, R. J.; Xiao, B.; Yang, S.; Wang, J. N.; Wang, Y.; Cowart, L. A.; Xiao,
X.; Wang, D. W.; Xia, Y. Regulation of endothelial nitric-oxide synthase activity through
phosphorylation in response to epoxyeicosatrienoic acids. Prostaglandins Other Lipid
Mediators 2007, 82 (1–4), 162–174.
16. Lindsley, C. W.; Zhao, Z.; Leister, W. H.; Robinson, R.; Barnett, S. F.; Defeo-Jones, D.;
Jones, R. E.; Hartman, G. D.; Huff, J. R.; Huber, H. E.; Duggan, M. E. Allosteric AKT
(PKB) inhibitors: Discovery and SAR of isozyme selective inhibitors. Bioorg. Med. Chem.
Lett. 2005, 15 (3), 761–764.
17. Noble, S.; Goa, K. L. Adefovir dipivoxil. Drugs 1999, 58 (3), 479–487, 488–489.
18. Tyring, S.; Barbarash, R. A.; Nahlik, J. E.; Cunningham, A.; Marley, J.; Heng, M.; Jones,
T.; Rea, T.; Boon, R.; Saltzman, R. Famciclovir for the treatment of acute herpes zoster:
Effects on acute disease and postherpetic neuralgia: A randomized, double-blind, placebo-
controlled trial. Ann. Internal Med. 1995, 123 (2), 89–96.